Jasper Therapeutics, Inc. Overview
Pro stress-test →Jasper Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious and rare diseases with unmet medical needs, particularly mast cell-driven disorders and hematologic complications. The company's lead candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor signaling through the CD117 receptor to deplete mast cells and address conditions like chronic spontaneous urticaria and asthma, while also serving as a conditioning agent for stem cell transplantation.
Strategic Profile
Pro stress-test →Jasper leverages engineered biologics and cell-based approaches to address complications in hematologic conditions and improve transplant outcomes. The company demonstrates strategic positioning in the rare disease and regenerative medicine space, with a focus on translating immunobiology advances into clinical solutions. Recently appointed CEO Jeet Mahal is leading the company through its next phase of clinical growth.
Competitive Landscape
Pro stress-test →Jasper competes in the clinical-stage biotech space against other companies developing mast cell targeted therapies and cell-based regenerative approaches. Key competitive dynamics include other monoclonal antibody developers and companies focused on hematopoietic stem cell transplantation improvements. Jasper's differentiated approach targeting CD117 on mast and stem cells positions it uniquely, but execution risks remain high in this competitive and capital-intensive sector.
Industry Context
Jasper Therapeutics, Inc. operates in Biopharmaceutical - Clinical Stage / Specialty Therapeutics.
Key facts
Founded: 2018 · Headquarters: Redwood City, California · Market cap: $49.3M